Frontiers | COVID-19 and Diabetes: Understanding the Interrelationship and Risks for a Severe Course
Why remdesivir, a highly effective COVID treatment, is a last resort : Shots - Health News : NPR
COVID-19 remdesivir study finds long hospital stay, but context matters | CIDRAP
World's top intensive care body advises against remdesivir for sickest COVID patients – EURACTIV.com
Corona-Arzt im Interview: „Remdesivir kann sehr hilfreich sein“
COVID-19: Behandlungsdauer mit Remdesivir kann halbiert werden
Remdesivir Reduced COVID-19 Mortality Rates Across All Variants
Remdesivir senkt laut Hersteller COVID-19-Sterberisiko
Remdesivir for severe covid-19: a clinical practice guideline | The BMJ
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial - The Lancet Infectious
Studie in „Cochrane“ zeigt: Remdesivir hat offenbar geringe bis keine Auswirkung auf Sterblichkeit von COVID-19-Patienten – AC forscht
COVID-19: Virologen hoffen auf gute Wirkung von Remdesivir
Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19 - The Lancet Infectious Diseases
Remdesivir Reduces Readmission Risk by 16% Among Immunocompromised Patients With COVID-19 - Specialty Pharmacy Continuum
Remdesivir zeigt Nutzen und schwere Nebenwirkungen | APOTHEKE ADHOC
COVID | Free Full-Text | Real-World Safety and Effectiveness of Remdesivir and Corticosteroids in Hospitalized Patients with COVID-19
Furcht vor neuem Ebola-Ausbruch in Westafrika – DW – 14.02.2021
Remdesivir: Empfehlungen zum Einsatz bei Covid-19 - DeutschesApothekenPortal
Illinois coronavirus: Remdesivir drug trial patient describes recovery from COVID-19 - ABC7 Chicago
Exploring remdesivir resistance in COVID-19-infected transplant recipients
EU makes €1 billion bet on Gilead's COVID drug before trial results – EURACTIV.com
SARS-CoV-2's resistance to remdesivir in vitro
Remdesivir activates urotensin II receptor and induces cardiomyocyte dysfunction
WHO: Remdesivir statt Antikörper | APOTHEKE ADHOC
Antiviral activity assessment of remdesivir against 10 current and former SARS-CoV-2 variant clinical isolates
